Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Gen Radioligand Therapies October 11, 2023
BriaCell Partners with NYCBS for Pivotal Ph3 Study of Bria-IMT in Advanced Breast Cancer October 11, 2023
Ankyra Therapeutics and Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors October 11, 2023
US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction October 11, 2023
EXKIVITY® (mobocertinib) to be voluntary withdrawn from the U.S. for adult patients with EGFR Exon20 insertion+ mNSCLC whose disease has progressed on or after platinum-based chemotherapy October 11, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
First Patient dosed in Landmark STAR-LLD Lenalidomide Ph 1b Trial in Multiple Myeloma October 11, 2023
Positive Interim Ph 2 ASPEN-06 Trial Results of Evorpacept in Advanced HER2+ve Gastric Cancer Reported October 11, 2023
KEYTRUDA® Met Primary Endpoint of DFS in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery October 11, 2023
U.S. FDA Fast Track Designation for KT-333 for the Treatment of R/R Cutaneous T-Cell Lymphoma and R/R Peripheral T-Cell Lymphoma October 11, 2023
FDA Grants Priority Review to KEYTRUDA + Concurrent ChemoRT as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer October 11, 2023
FDA Accepts for Priority Review Supplemental NDA for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced RCC October 11, 2023
